CA2563162A1 - Forme posologique contenant du pantoprazole en tant qu'ingredient actif - Google Patents
Forme posologique contenant du pantoprazole en tant qu'ingredient actif Download PDFInfo
- Publication number
- CA2563162A1 CA2563162A1 CA002563162A CA2563162A CA2563162A1 CA 2563162 A1 CA2563162 A1 CA 2563162A1 CA 002563162 A CA002563162 A CA 002563162A CA 2563162 A CA2563162 A CA 2563162A CA 2563162 A1 CA2563162 A1 CA 2563162A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- form according
- pantoprazole
- pellet
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 title claims abstract 34
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title claims abstract 12
- 229960005019 pantoprazole Drugs 0.000 title claims abstract 12
- 239000004480 active ingredient Substances 0.000 title 1
- 159000000003 magnesium salts Chemical class 0.000 claims abstract 8
- 239000008188 pellet Substances 0.000 claims 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 11
- 239000010410 layer Substances 0.000 claims 11
- RDRUTBCDIVCMMX-UHFFFAOYSA-N magnesium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical class [Mg+2].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC.COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC RDRUTBCDIVCMMX-UHFFFAOYSA-N 0.000 claims 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 238000009498 subcoating Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 4
- 229920000881 Modified starch Polymers 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 4
- 150000002484 inorganic compounds Chemical class 0.000 claims 4
- 229910010272 inorganic material Inorganic materials 0.000 claims 4
- 235000017550 sodium carbonate Nutrition 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 239000008107 starch Substances 0.000 claims 4
- 239000007858 starting material Substances 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 3
- 229960000913 crospovidone Drugs 0.000 claims 3
- 208000000718 duodenal ulcer Diseases 0.000 claims 3
- 239000012055 enteric layer Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 3
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 3
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 2
- 210000004051 gastric juice Anatomy 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000004408 titanium dioxide Substances 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03010328 | 2003-05-08 | ||
| EP03010328.7 | 2003-05-08 | ||
| EP04001754.3 | 2004-01-28 | ||
| EP04001754 | 2004-01-28 | ||
| CA002489140A CA2489140C (fr) | 2003-05-08 | 2004-05-07 | Forme posologique contenant du pantoprazole en tant qu'ingredient actif |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002489140A Division CA2489140C (fr) | 2003-05-08 | 2004-05-07 | Forme posologique contenant du pantoprazole en tant qu'ingredient actif |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2563162A1 true CA2563162A1 (fr) | 2004-11-18 |
| CA2563162C CA2563162C (fr) | 2012-07-10 |
Family
ID=37480467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2563162A Expired - Lifetime CA2563162C (fr) | 2003-05-08 | 2004-05-07 | Forme posologique contenant du pantoprazole en tant qu'ingredient actif |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2563162C (fr) |
-
2004
- 2004-05-07 CA CA2563162A patent/CA2563162C/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2563162C (fr) | 2012-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1879566B1 (fr) | Compositions et methodes permettant d'empecher les secretions d'acide gastrique | |
| HRP20121005T1 (hr) | Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak | |
| ES2376466T3 (es) | Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación. | |
| CN101002939A (zh) | 一类治疗与胃酸有关疾病的药物组合制剂 | |
| SK278566B6 (en) | A medicament in the pellet or tablet form for the oral | |
| US20070160664A1 (en) | Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent | |
| CA2524979A1 (fr) | Forme posologique contenant du (s)-pantoprazole en tant qu'ingredient actif | |
| US9370481B2 (en) | Compositions and methods for inhibiting gastric acid secretion | |
| US9233092B2 (en) | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI | |
| EP1210091A1 (fr) | Traitement des aigreurs d'estomac | |
| KR20140140353A (ko) | 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물 | |
| CA2563162A1 (fr) | Forme posologique contenant du pantoprazole en tant qu'ingredient actif | |
| US20240100087A1 (en) | Pharmaceutical composition comprising proton pump inhibitor and antacid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |